BCMA

Assets acting on this target.

Class
BCMA-directed therapy (B-cell maturation antigen)
Pathway
Fully human anti-BCMA scFv (25C2) with CD8α hinge/transmembrane domain, 4-1BB costimulatory domain and CD3ζ signaling domain; NMPA-approved Feb 2024 for relapsed/refractory multiple myeloma (China)

B-cell maturation antigen (BCMA), also known as TNFRSF17, is a cell-surface receptor expressed almost exclusively on mature B lymphocytes and, at high density, on plasma cells, the antibody-producing cells that become malignant in multiple myeloma. BCMA binds two ligands, APRIL and BAFF, and this engagement drives downstream NF-κB signaling that supports plasma cell survival and proliferation. Because malignant plasma cells depend heavily on this survival signal and display BCMA uniformly, the receptor serves as a distinguishing marker that can be exploited therapeutically, largely independent of the survival pathway itself. Chimeric antigen receptor (CAR) T-cell therapy re-engineers a patient's own T lymphocytes to express a synthetic receptor whose extracellular portion recognizes BCMA and whose intracellular portion triggers T-cell activation, bypassing the need for conventional antigen presentation. This allows the engineered T cells to recognize and eliminate BCMA-bearing tumor cells directly. The broader disease relevance of BCMA-directed therapy spans multiple myeloma and, in principle, other plasma-cell and B-cell disorders where this receptor is expressed, making it one of the most actively pursued targets across cellular, antibody-conjugate, and bispecific antibody modalities.

By indication

Related mechanisms

BCMA drugs compared

30 drugs, stage by indication
30 drugs acting on BCMA: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Belantamab mafodotinGlaxoSmithKlineantibody-drug conjugate (anti-BCMA, MMAF payload)ApprovedApproved in Multiple Myeloma
Ciltacabtagene autoleucelJohnson & Johnson, Legend Biotech CorporationCAR-T (autologous cellular therapy)ApprovedApproved in Multiple Myeloma
Idecabtagene vicleucelBristol-Myers Squibbcell therapy (autologous CAR-T)ApprovedApproved in Multiple Myeloma
Anitocabtagene autoleucelGilead SciencesCAR-T (autologous cellular therapy)Phase 3Phase 3 in Multiple Myeloma
Equecabtagene autoleucelIASO BiotherapeuticsCAR-T cell therapy (fully-human anti-BCMA)Phase 3Phase 3 in Multiple Myeloma
Hrain anti-BCMA CAR-THrain Biotechnology Co., Ltd.cell therapy (autologous BCMA-targeted CAR-T)Phase 2Phase 2 in Multiple Myeloma
HRC0202Hrain Biotechnology Co., Ltd.CAR-T (autologous, BCMA-directed)Phase 2Phase 2 in Multiple Myeloma
AZD4045AstraZenecaallogeneic CAR-T cell therapy (anti-BCMA)Phase 1/2Phase 1/2 in Multiple Myeloma
BCMA CAR-NK (Shenzhen Pregene Biopharma)Shenzhen Pregene Biopharma Co., Ltd.allogeneic CAR-NK cell therapyPhase 1/2Phase 1/2 in Multiple Myeloma
BCMA-targeted Prime CAR-T cells (Chongqing Precision Biotech)Chongqing Precision Biotech Co., LtdCAR-T cell therapyPhase 1/2Phase 1/2 in Multiple Myeloma
BelantamabGlaxoSmithKlinemonoclonal antibody (non-conjugated)Phase 1/2Phase 1/2 in Multiple Myeloma
Pamlectabart tismanitinHeidelberg Pharma AG, Huadong Medicineantibody-drug conjugatePhase 1/2Phase 1/2 in Multiple Myeloma
SENL103Hebei Senlang Biotechnologycell therapy (CAR-T)Phase 1/2Phase 1/2 in Multiple Myeloma
Trovocabtagene autoleucel (C-CAR088)AbelZeta Pharma, Inc.CAR-T cell therapyPhase 1/2Phase 1/2 in Multiple Myeloma
Zevorcabtagene autoleucelCARsgen Therapeutics Holdings Limited, Hangzhou Zhongmei Huadong Pharmaceuticalcell therapy (autologous BCMA-targeted CAR-T)Phase 1/2Phase 1/2 in Multiple Myeloma
ALLO-715Allogene Therapeutics, Inc.cell therapy (allogeneic anti-BCMA CAR-T)Phase 1Phase 1 in Multiple Myeloma
BCMA CAR-NK (Hrain)Hrain Biotechnology Co., Ltd.cell therapy (allogeneic BCMA-targeted CAR-NK)Phase 1Phase 1 in Multiple Myeloma
BP2202BrightPath Biotherapeutics Co., Ltd.cell therapyPhase 1Phase 1 in Multiple Myeloma
CART-BCMAShanghai Simnova Biotechnology Co., Ltd.CAR-T cell therapyPhase 1Phase 1 in Multiple Myeloma
CBG002Zhejiang Carbiogene Therapeutics Co., Ltd.CAR-T (autologous)Phase 1Phase 1 in Multiple Myeloma
FT576Fate Therapeuticscell therapy (allogeneic iPSC-derived CAR-NK)Phase 1Phase 1 in Multiple Myeloma
IM21 CAR-T cellsBeijing Immunochina Medical Science & Technology Co., Ltd.CAR-T cell therapyPhase 1Phase 1 in Multiple Myeloma
IMV102Suzhou Immunofoco Biotechnology Co., Ltd.gene therapy (in vivo lentiviral CAR-T)Phase 1Phase 1 in Multiple Myeloma
KLN-1010Kelonia Therapeutics, Inc.gene therapy (in vivo lentiviral gene delivery)Phase 1Phase 1 in Multiple Myeloma
P-BCMA-ALLO1Poseida Therapeutics, Inc.cell therapy (allogeneic CAR-T)Phase 1Phase 1 in Multiple Myeloma
UF-KURE-BCMAKure Cells, Inc.CAR-T cell therapy (autologous, anti-BCMA)Phase 1Phase 1 in Multiple Myeloma
UWD-00BWondercel Biotech (Shenzhen) Co., Ltd.cell therapy (universal/allogeneic CAR-T)Phase 1Phase 1 in Multiple Myeloma
BCMA-CART (Bioray Laboratories)BioRay Laboratories (Shanghai Bangyao Biotechnology Co., Ltd.)CAR-T cell therapyStage not recordedNot recorded
BRL-305BioRay Laboratories (Shanghai Bangyao Biotechnology Co., Ltd.)cell therapy (allogeneic CAR-T)Stage not recordedNot recorded
UTAA17PersonGen BioTherapeutics (Suzhou) Co., Ltd.cell therapy (gamma-delta T CAR-T)Stage not recordedNot recorded

← all mechanisms